Tag: equity
-
$150 Million Raised for NYC Life Science Start-Ups
1 April 2015. A consortium of public and private funding sources raised $150 million to invest in new life science companies located in New York City. The Early Stage Life Sciences Funding Initiative exceeded its original $100 million goal by half, and seeks to start 15 to 20 new businesses in New York by 2020,…
-
Novartis, Aduro Biotech Partner on Cancer Immunotherapy
30 March 2015. The pharmaceutical company Novartis is licensing cancer immunotherapy technology from Aduro Biotech in Berkeley, California. The collaboration could earn Aduro as much as $750 million, including an equity stake, for access to its work on cyclic dinucleotides, still in preclinical study, but considered promising as a cancer treatment. Cyclic dinucleotides are naturally…
-
Stem Cell Biotech Gains $44M in First Venture Round
24 March 2015. A biotechnology start-up developing a stem-cell technology to replace missing beta cells that produce insulin for patients with type 1 diabetes, secured $44 million in its first venture funding round. Funding for Semma Therapeutics in Cambridge, Massachusetts was led by MPM Capital, with participation by Fidelity Biosciences, ARCH Venture Partners, and Medtronic.…
-
Immunotherapy Biotech Raising $45 Million in IPO
12 March 2015. Genocea Biosciences Inc., a biotechnology company developing immunotherapies to treat genital herpes and other diseases, is raising $45 million in its initial public offering of stock. The Cambridge, Massachusetts enterprise is issuing 5,454,545 shares priced at $8.25. The company trades on the NASDAQ exchange under the symbol GNCA. As of 12:00 pm…
-
Gates Invests, Supports R&D in RNA Vaccine Maker
6 March 2015. The Bill and Melinda Gates Foundation is making an equity investment and providing a grant to support research at CureVac GmbH, a developer of vaccines and therapies with RNA molecules. The foundation is investing €46 million ($52 million) in CureVac, in Tübingen, Germany, but the amount of the grant supporting research in…
-
Illumina Adds $40M for Genomic Accelerator Start-Ups
26 February 2015. Illumina Inc., a developer of genomic analysis systems, is adding $40 million for investments in new enterprises based on genomic science that graduate from its accelerator program. The additional financing is provided by Viking Global Investors, an equity and hedge fund investment company in Greenwich, Connecticut. The Illumina Accelerator program provides promising…
-
Bristol-Myers Squibb Acquires Biotech Cancer Therapies
24 February 2015. Bristol-Myers Squibb is purchasing biotechnology company Flexus Biosciences Inc., gaining many of that company’s cancer therapies in a deal valued as much as $1.25 billion to Flexus’s shareholders. The deal allows Flexus Biosciences shareholders to spin-off a new enterprise to develop the remaining drug programs, including treatments for cancer. The acquisition gives…
-
Redesigned Crutch Developer Gains $450K in Early Funds
17 February 2015. A company developing a more comfortable alternative to standard underarm or forearm crutches, secured $450,000 in its first venture funding round. Financing for Better Walk Inc., a spin-off from Georgia Institute of Technology and based in Atlanta, is led by MB Venture Partners, a Memphis-based venture capital firm. A broken ankle playing basketball…
-
Image Analysis Company Raises $800K for New Venture
16 February 2015. Glencoe Software Inc., a developer of image analysis and management software for research and pharmaceutical applications, raised $800,000 to fund a new venture in digital pathology. Financing for the Seattle company’s venture is provided by TIE Angels Group – Seattle and several other local angel investors. Glencoe is the commercialization arm of…
-
Intrexon Acquires Biopharm Company for $60M
13 February 2015. Intrexon Corp., a biotechnology company in Gaithersburg, Maryland specializing in synthetic biology, is acquiring ActoGeniX, developing biologic therapies from engineered microbes. Under the deal, stockholders of ActoGeniX, based in Ghent, Belgium, are receiving $30 million in cash plus another $30 million in Intrexon stock. ActoGeniX develops therapies from engineered microbes, particularly Lactococcus…